X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3591) 3591
Publication (486) 486
Newsletter (78) 78
Newspaper Article (38) 38
Book Review (36) 36
Magazine Article (16) 16
Book Chapter (15) 15
Dissertation (14) 14
Conference Proceeding (5) 5
Trade Publication Article (2) 2
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
efavirenz (3219) 3219
humans (2044) 2044
index medicus (1641) 1641
hiv infections - drug therapy (1475) 1475
infectious diseases (1316) 1316
male (1268) 1268
hiv (1251) 1251
female (1236) 1236
adult (1111) 1111
antiretroviral therapy (907) 907
pharmacology & pharmacy (877) 877
immunology (755) 755
middle aged (740) 740
anti-hiv agents - therapeutic use (714) 714
nevirapine (682) 682
antiviral agents (636) 636
human immunodeficiency virus--hiv (555) 555
therapy (542) 542
drug therapy (541) 541
antiretroviral drugs (539) 539
virology (529) 529
hiv infection (522) 522
pharmacokinetics (480) 480
highly active antiretroviral therapy (463) 463
tenofovir (447) 447
microbiology (442) 442
treatment outcome (432) 432
research (424) 424
hiv infections - virology (418) 418
anti-hiv agents - adverse effects (407) 407
aids (404) 404
anti-hiv agents - administration & dosage (398) 398
viral load (397) 397
lamivudine (396) 396
protease inhibitors (379) 379
hiv-1 - drug effects (374) 374
emtricitabine (363) 363
cd4 lymphocyte count (344) 344
health aspects (333) 333
analysis (332) 332
hiv-1 (328) 328
reverse transcriptase inhibitors - therapeutic use (327) 327
benzoxazines - therapeutic use (307) 307
dosage and administration (305) 305
antiretroviral agents (302) 302
risk factors (288) 288
drug therapy, combination (287) 287
aids/hiv (284) 284
antiretroviral therapy, highly active (278) 278
drugs (278) 278
hiv-infected patients (274) 274
infection (271) 271
young adult (267) 267
acquired immune deficiency syndrome--aids (259) 259
virus diseases (258) 258
ritonavir (257) 257
efficacy (256) 256
safety (250) 250
zidovudine (250) 250
adolescent (242) 242
human immunodeficiency virus (242) 242
hiv-1-infected patients (241) 241
article (240) 240
care and treatment (239) 239
hiv infections - complications (237) 237
anti-hiv agents - pharmacokinetics (231) 231
drug interactions (231) 231
benzoxazines - administration & dosage (229) 229
pharmacogenetics (229) 229
adults (225) 225
anti-hiv agents - pharmacology (222) 222
hiv patients (221) 221
hiv-1 - genetics (221) 221
reverse-transcriptase inhibitors (220) 220
benzoxazines - adverse effects (211) 211
medicine (208) 208
adherence (203) 203
lopinavir (203) 203
drug resistance (202) 202
benzoxazines (198) 198
patients (197) 197
tuberculosis (197) 197
aged (195) 195
mutation (195) 195
research article (195) 195
complications and side effects (193) 193
adenine - analogs & derivatives (192) 192
prospective studies (191) 191
benzoxazines - pharmacokinetics (190) 190
reverse transcriptase inhibitors - adverse effects (186) 186
human-immunodeficiency-virus (185) 185
genotype (184) 184
clinical trials (183) 183
active antiretroviral therapy (182) 182
toxicity (181) 181
cohort studies (180) 180
anti-hiv agents (179) 179
pharmacology (176) 176
retrospective studies (175) 175
cyp2b6 (174) 174
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3622) 3622
Spanish (57) 57
French (36) 36
German (17) 17
Portuguese (10) 10
Japanese (4) 4
Polish (3) 3
Chinese (2) 2
Afrikaans (1) 1
Dutch (1) 1
Italian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 2011, Volume 154, Issue 7, pp. 445 - 456
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign,... 
Atazanavir | Ritonavir | Research | Drug therapy | Health aspects | Efavirenz | HIV infection
Journal Article
Rapid communications in mass spectrometry : RCM, ISSN 0951-4198, 4/2018, Volume 32, Issue 8, pp. 657 - 664
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 12/2019, Volume 140, p. 105068
Maternofoetal physiologically-based pharmacokinetic models integrating multi-compartmental maternal and foetal units were developed using Simbiology® to... 
Pregnancy | Fetus | Efavirenz | Thalidomide | PBPK model
Journal Article
09/2013
Background: There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future... 
once-a-day therapy | Lamivudine and Efavirenz | Didanosine | child
Web Resource
Frontiers in Bioscience - Landmark, ISSN 1093-9946, 01/2018, Volume 23, Issue 7, pp. 1292 - 1309
Journal Article
LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2014, Volume 14, Issue 7, pp. 572 - 580
Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether dual... 
INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | SAFETY | ANALOGS | EFAVIRENZ | LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | SPARING REGIMEN | TENOFOVIR/EMTRICITABINE
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 10/2019, Volume 570, p. 118597
Efavirenz (EFZ) and tenofovir disoproxil fumarate (TDF) can be used simultaneously in the treatment of human immunodeficiency virus type1 infection. In this... 
Eutectic mixture | Efavirenz | Dissolution | Tenofovir disoproxil fumarate | Solubility
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 07/2018, Volume 104, Issue 1, pp. 130 - 138
CYP2B6*6 and CYP2B6*18 are the most clinically important variants causing reduced CYP2B6 protein expression and activity. However, these variants do not... 
SNP | polymorphism | metabolism | CYP | bupropion | pharmacogenetics | efavirenz
Journal Article
Journal Article
Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2016, Volume 6, Issue 5, pp. 413 - 425
Mounting evidence demonstrates that CYP2B6 plays a much larger role in human drug metabolism than was previously believed. The discovery of multiple important... 
Cyclophosphamide | CYP2B6 | CAR | PXR | Drug-drug interaction | Efavirenz | Polymorphism | HUMAN CYTOCHROME P4502B6 | PATIENT-CONTROLLED ANALGESIA | EFAVIRENZ-CONTAINING REGIMENS | HUMAN LIVER-MICROSOMES | PREGNANE-X-RECEPTOR | DISRUPTOR PESTICIDE-METHOXYCHLOR | CONSTITUTIVE ANDROSTANE RECEPTOR | PHARMACOLOGY & PHARMACY | IN-VITRO BIOTRANSFORMATION | HUMAN CYP2B6 GENE | RESPONSIVE ENHANCER MODULE | IFA, Ifosfamide | DEX, dexamethasone | HNF, hepatocyte nuclear factor | Review | CITCO, (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) | NVP, nevirapine | 2, nuclear receptor binding site 1 | GRE, glucocorticoid responsive element | MAOI, monoamine oxidase inhibitor | PXR, pregnane X receptor | CYP, cytochrome P450 | enhancer-binding protein | UGT, UDP-glucuronosyl transferase | PCN, pregnenolone 16 alpha-carbonitrile | PBREM, phenobarbital-responsive enhancer module | Drug–drug interaction | EBP, CCAAT | CAR, constitutive androstane receptor | COUP-TF, chicken ovalbumin upstream promoter-transcription factor | ERE, estrogen responsive element | HAART, highly active antiretroviral therapy | NR1 | PB, phenobarbital | NNRTI, non-nucleotide reverse-transcriptase inhibitor | CPA, cyclophosphamide | SNP, single nucleotide polymorphism | TCPOBOP, 1,4-bis[3,5-dichloropyridyloxy]benzene | CHOP, cyclophosphamide–doxorubicin–vincristine–prednisone | 4-OH-CPA, 4-hydroxycyclophosphamide | DDI, drug–drug interaction | EFV, efavirenz | GR, glucocorticoid receptor | E2, estradiol | RIF, rifampin
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 07/2004, Volume 319, Issue 4, pp. 1322 - 1326
Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver. We analyzed the genotypes of CYP2B6 and their contribution to plasma EFV... 
HIV-1 | Cytochrome P450 | Genetic polymorphism | Plasma concentration | Efavirenz
Journal Article
Journal Article